4 Questions to Ask Your Doctor About Breast Cancer-Related Lymphedema

In a recent interview with CURE, Dr. Sheri Prentiss, a physician and breast cancer survivor, shared her perspective on a critical yet often-overlooked aspect of the cancer journey: breast cancer-related lymphedema. While the primary objective of any oncology team is the eradication of cancer, Prentiss emphasized that the success of modern treatments means patients are living longer, making long-term quality of life an essential component of care.

Prentiss noted that physicians sometimes hesitate to discuss side effects such as lymphedema immediately after a "massive diagnosis" to avoid overwhelming the patient. However, she argued that survivorship planning must begin early. To ensure a life of function and comfort after treatment, Prentiss outlined four pivotal questions every patient should ask their care team to advocate for their own lymphatic health.

First, patients must understand their individual risk factors. "There are differences depending upon the type of surgery you’ve had, the type of chemotherapy ... [and] did you receive regional radiation?" Prentiss explained. Factors such as taxane-based chemotherapy or post-surgical complications can further stratify a patient's risk, making personalized assessment vital.

Second, Prentiss urged patients to inquire about the availability of a formal lymphedema prevention program. If an institution does not offer one, patients should ask for a referral to a facility where specialized lymphedema care is a priority.

Third, the tools used for detection are paramount. Prentiss highlighted the importance of catching fluid changes before they become visible to the naked eye. She specifically mentioned bioimpedance spectroscopy, such as L-Dex testing on a SOZO device, which can identify a difference as small as 2.4 tablespoons of fluid between limbs. This early "subclinical" detection allows for immediate intervention, preventing the progression into chronic, disabling lymphedema.

Finally, Prentiss addressed the timeline of monitoring. Lymphedema is not always an immediate post-operative concern; it can develop three years or more after treatment has concluded. Patients should ask their providers how long they will be monitored long-term to ensure that any late-onset swelling is caught and managed.

By asking these questions, patients shift the conversation from mere survival to a focus on long-term wellness. As Prentiss suggested, advocating for early detection and risk stratification is the key to maintaining a high quality of life well beyond the conclusion of cancer treatment.

For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.